## What is claimed is:

- 1. A disposable solid test strip capable of enabling a person to self-monitor fat loss on a daily basis in a fluid sample of urine, saliva, or sweat or other bodily fluid by providing a color signal, a photochemical signal or an electrochemical signal indicative of at least the β-hydroxybutyrate content of the sample upon being dipped in said sample, removed, allowed to rest briefly and then read.
- 2. A disposable solid test strip according to Claim 1 wherein the color,  $photochemical\ signal\ or\ electrochemical\ signal\ is\ indicative\ of\ the\ combined\ \beta hydroxybutyrate\ and\ acetoacetate\ content\ of\ the\ sample.$
- 3. A disposable solid test strip according to Claim 1 wherein the color, photochemical signal or electrochemical signal is indicative of the content of total ketone bodies present in the sample.
- 4. A solid test strip according to Claim 1 which comprises
  - 1) an inert support layer and
  - a dried reagent layer comprising a porous material impregnated with
    - a)  $\beta$ -hydroxybutyrate dehydrogenase enzyme (" $\beta$  HBD")
    - b) nicotinamide adenine dinucleotide ("NAD"),
    - c) a tetrazolium dye precursor

- an electron mediator capable of transferring an electron to said dye precursor to effect a color change and
- e) a sufficient quantity of a buffer having a pH of from about 8.6 to about 9.5 to maintain the reaction pH at a level between about 8.6 and about 9.5 when the strip is saturated with a sample of bodily fluid.
- 5. A solid test strip according to Claim 4 in which the  $\beta$ -HBD enzyme is obtained from *Alcaligenes* or another source which contains  $\beta$ -HBD that is not inhibited by chloride ions and is present in an amount of from about 0.2 to about 5.0 U per strip.
- 6. A solid test strip according to Claim 4 wherein the tetrazolium dye precursor is nitrobluetetrazolium ("NBT") or 2-(indophenyl)-3-(paranitrophenyl)-5-phenyl tetrazolium chloride ("INT").
- 7. A solid test strip according to Claim 4 wherein the β-hydroxybutyrate is from a source that is inhibited by chloride ions and is present in an amount per strip from about 1 to about 100 U per strip.
- 8. A solid test strip according to Claim 4 wherein the electron mediator is a diaphorase enzyme.

- 9. A test strip according to Claim 2 which is comprised of
  - 1) a inert support layer, and
  - 2) a dried reagent layer comprising a porous material impregnated with:
    - a)  $\beta$ -HBD enzyme
    - b) NAD
    - c) a tetrazolium dye precursor,
    - an electron mediator capable of transferring an electron to
       said dye precursor to effect a color change and
    - e) a sufficient quantity of a buffer having a pH between about 7.0 and about 8.3 to maintain the reaction pH between about 7.0 and about 8.3 when the strip is saturated with sample.
- 10. A test strip according to claim 9 wherein the  $\beta$ -BHD is obtained from Alcaligenes or another source found to produce  $\beta$ -HBD that is uninhibited by chloride ions and is present in an amount of from about 0.2 to about 5.0 U per strip.
- 11. A test strip according to claim 9 wherein the β-HBD is obtained from a source such that it is inhibited by chloride ions, and it is present in an amount per strip from about 1 to about 100 U per strip.
- 12. A test strip according to Claim 9 wherein the tetrazolium dye precursor is NBT or INT.

- A test strip according to Claim 9 wherein the electron mediator is a diaphorase enzyme.
- 14. A test strip according to Claim 2 comprising:
  - 1) an inert support layer and
  - 2) a dried reagent layer comprising a porous material impregnated with:
    - a) NAD,
    - b)  $\beta$ -HBD,
    - c) a nitroprusside salt or a diazonium salt in a quantity sufficient to react with endogenous acetoacetate in the sample and acetoacetate obtained by conversion thereto of  $\beta$ -hydroxybutyrate in the sample,
    - d) a tetrazolium dye precursor,
    - e) an electron mediator,
    - f) and a sufficient quantity of a buffer having a pH from about 8.6 to about 9.5 to maintain the strip at a level pH of about 8.6 to about 9.5 when saturated with sample.
- 15. A test strip according to Claim 14 wherein the  $\beta$ -HBD is from a source selected from among *Alcaligenes* and others capable of producing  $\beta$ -HBD that is uninhibited by chloride ions and is present in an amount of from about 0.2 to about 5.0 U per strip.

- 16. A test strip according to Claim 14 wherein the β-HBD is obtained from a source such that it is inhibited by chloride ions and is present in an amount per strip from about 1 to about 100 U per strip.
- A test strip according to Claim 14 wherein the electron mediator is a diaphorase enzyme.
- 18. A test strip according to Claim 14 wherein the tetrazolium dye precursor is NBT or INT.
- A test strip according to Claim 14 wherein ingredient (c) is sodium nitroprusside.
- 20. A test strip according to Claim 14 wherein ingredient (c) is a diazonium salt.
- 21. A test strip according to Claim 20 wherein ingredient (c) is 4-nitrobenzene diazonium fluoborate.
- 22. A test strip according to claim 2 comprising
  - 1) an inert support layer
  - 2) a dried reagent layer comprising a porous material impregnated with:
    - a) NAD
    - b)  $\beta$ -HBD
    - a nitroprusside salt or a diazonium salt in a quantity
       sufficient to react with endogenous acetoacetate in the
       sample and acetoacetate obtained by conversion thereto of
       β-hydroxybutyrate in the sample,

- d) and a sufficient quantity of a buffer having a pH from about 8.6 to about 9.5 to maintain the strip at a level of about 8.6 to about 9.5 when saturated with a sample from the group consisting of urine, saliva and sweat.
- 23. A test strip according to Claim 22 wherein the β-HBD is from a source selected from among *Alcaligenes* and others capable of producing β-HBD that is uninhibited by chloride ions and is present in an amount from about 0.2 to about 5.0 U per strip.
- 24. A test strip according to Claim 22 wherein the  $\beta$ -HBD is obtained from a source such that it is inhibited by chloride ions and is present in an amount per strip from about 1 to about 100 U per strip.
- 25. A test strip according to Claim 22 wherein the ingredient (c) is a nitroprusside salt.
- 26. A test strip according to Claim 25 wherein ingredient (c) is sodium nitroprusside.
- 27. A test strip according to Claim 22 wherein ingredient (c) is a diazonium salt.
- 28. A test strip according to Claim 27 wherein ingredient (c) is 4 nitrobenzene diazonium fluoborate.

- 29. A test strip according to Claim 3 comprising
  - 1) an inert support layer and
  - 2) a dried reagent layer comprising
    - a) β-HBD
    - b) NAD
    - c) nitroprusside salt or a diazonium salt in sufficient quantity
      to
      - (i) immediately react with the acetone present in the sample and stabilize it against volailization
      - (ii) also react with the endogenous acetoacetate in the sample and with acetoacetate obtained by conversion thereto of  $\beta$ -hydroxybutyrate in the sample
    - a sufficient quantity of a buffer having a pH from about 8.6 up to about 9.5 to maintain the reaction pH between about 8.6 and about 9.5 when the strip is saturated with sample.
- 30. A test strip according to Claim 29 wherein the β-HBD is obtained from Alicaligenes or another source such that it is not inhibited by chloride ions and it is present in an amount of about 0.2 to 5.0 U per strip.

- 31. A test strip according to Claim 29 wherein the  $\beta$ -HBD is obtained from a source such that it is inhibited by chloride ions and it is present in an amount from 1.0 to about 100 U per strip.
- 32. A test strip according to Claim 29 in which the salt is a nitroprusside salt.
- 33. A test strip according to Claim 32 in which the nitroprusside salt is sodium nitroprusside.
- 34. A test strip according to Claim 29 in which the salt is a diazonium salt.
- 35. A test strip according to Claim 34 in which the diazonium salt is 4-nitrobenzene diazonium fluoborate.
- 36. A method for monitoring the level of β-hydroxybutyrate present in a sample of human bodily fluid which comprises contacting a sample of said fluid with a mixture of
  - a)  $\beta$ -HBD which has been obtained from a *Alcaligenes* or another source such that is uninhibited by chloride ions,
  - b) NAD.
  - c) a tetrazolium dye precursor,
  - an electron mediator capable of transferring an electron to said
     dye precursor to effect a color change and
  - e) a buffer having a pH of from about 8.6 to about 9.5, and measuring by electrochemical, spectrophotometric or fluorometric means, or by comparison of the color developed to a preestablished color intensity standard, the amount of  $\beta$ -hydroxybutyrate in the sample.

- 37. A method according to Claim 36 wherein the tetrazolium dye precursor is NBT or INT.
- 38. A method according to Claim 36 wherein the electron mediator is a diaphorase enzyme.
- 39. A method for monitoring the level of combined acetoacetate and  $\beta$ hydroxybutyrate present in a sample of human bodily fluid which comprises
  contacting the sample with a mixture comprising the following ingredients:
  - a)  $\beta$ -HBD which has been obtained from *Alcaligenes* or another source such that it is not inhibited by chloride ions,
  - b) NAD,
  - c) a tetrazolium dye precursor,
  - an electron mediator capable of transferring an electron to said
     dye precursor to effect a color change, and
  - e) a buffer having a pH from about 7.0 to about 8.3, and measuring by electrochemical, spectrophotometric or fluorometric means, or by comparison of the color developed to a preestablished color intensity standard, the amount of  $\beta$ -hydroxybutyrate plus acetoacetate present in the sample.
- 40. A method according to Claim 39 wherein the tetrazolium dye precursor is NBT or INT.
- 41. A method according to Claim 39 wherein the electron mediator is diaphorase enzyme.

- 42. A method for monitoring the level of combined β hydroxybutyrate an acetoacetate present in a sample of human bodily fluid which comprise contacting said sample with a mixture comprising the following ingredients:
  - a)  $\beta$ -HBD which has been obtained from *Alcaligenes* or another source such that is is not inhibited by chloride ions,
  - b) NAD,
  - c) a nitroprusside salt of react with endogeous acetoacetate in the sample and acetoacetate obtained by conversion thereto of  $\beta$ -hydroxyrate in the sample, and
- d) a buffer having a pH of from about 8.6 to about 9.5 and measuring by electrochemical, spectrophotometric or fluorometric means, or by comparison of the color developed to a preestablished color intensity standard, the amount of combined acetoacetate and  $\beta$ -hydroxybutyrate in the sample.
- 43. A method according to Claim 42 wherein ingredient (c) is a nitroprusside salt.
- 44. A method according to Claim 43 in which the nitroprusside salt is sodium nitroprusside.
- 45. A method according to Claim 42 wherein ingredient (c) is a diazonuim salt.
- 46. A method according to Claim 45 wherein the diazonium salt is 4- nitrobenzen-diazonium.

- 47. A method according to Claim 42 having increased sensitivity wherein a tetrazolium dye precursor and an electron mediator are included in the mixture in addition to ingredients (a), (b), (c) and (d).
- 48. A method according to Claim 47 in which the tetrazolium dye precusor is NBT or INT and the electron mediator is a diaphorase enzyme.
- 49. A method for monitoring the level of total ketone bodies in a sample of human bodily fluid which comprises contacting said sample with a mixture containing the following ingredients:
  - a)  $\beta$ -HBD which has been obtained from *Alcaligenes* or another source such that it is not inhibited by chloride ions,
  - b) NAD,
  - c) a nitroprusside or diazonium salt in a quantity sufficient to
    - (i) react instantaneously with and stabilize against volatilization the acetone in the sample,
    - (ii) react with endogenous acetoacetate in the sample and
    - (iii) react with acetoacetate formed by conversion thereto to  $\beta$ hydroxybutyrate in the sample, and
  - d) a buffer having pH of from about 8.6 to about 9.5 and measuring by electrochemical, spectrophotometric or fluorometic means, or by comparison of the color developed to a preestablished color intensity standard, the amount of total ketone bodies in the sample.

- 50. A method according to Claim 49 wherein & ingredient (c) is a nitroprusside salt.
- 51. A method according to Claim 50 wherein ingredient (c) is sodium nitroprusside.
- 52. A method according to Claim 51 wherein ingredient (c) is a diazonium salt.
- 53. A method according to Claim 52 wherein ingredient (c) is 4-nitrobenzene diazonium fluoborate.
- 54. A method for monitoring the level of β-hydroxybutyrate present in a sample of human bodily fluid which comprises contacting a sample of said fluid with a mixture containing the following ingredients:
  - a) at least 20 U per milliliter ("ml.") of  $\beta$ -HBD obtained from a source such that it is inhibited by chloride ions,
  - b) NAD,
  - c) a tetrazolium dye precursor,
  - d) an electron mediator capable of transferring an electron to said
     dye precursor to effect a color change and
- e) a buffer having a pH of from about 8.6 to 9.5, and measuring by electrochemical, spectrophotometric or fluorometric means or by comparison of the color developed to a preestablished color intensity standard, the amount of  $\beta$ -hydroxybutyrate in the sample.

- 55. A method according to Claim 54 wherein the tetrazolium dye precursor in NBT or INT.
- 56. A method according to Claim 54 wherein the electron mediator is a diaphorase enzyme.
- 57. A method for monitoring the level of combined acetoacetate and β-hydroxybutyrate present in a sample of human bodily fluid which comprises contacting the sample with a mixture comprising the following ingredients:
  - a) at least 20 U per ml of  $\beta$ -HBD which has been obtained from a source such that it is inhibited by chloride ions,
  - b) NAD,
  - c) a tetrazolium dye precursor,
  - an electron mediator capable of transferring an electron to said
     dye precursor to effect a color change and
- e) a buffer having a pH from about 7.0 to about 8.3, and measuring by electrochemical, spectrophotometric or fluorometric means, or by comparison of the color developed to a preestablished color intensity standard, the amount of acetoacetate plus  $\beta$ -hydroxybutyrate present in the sample.
- 58. A method according to claim 57 wherein the tetrazolium dye precursor is NBT or INT.
- 59. A method according to claim 57 wherein the electron mediator is diaphorase enzyme.

- 60. A method for monitoring the level of combined β-hydroxbutyrate and acetoacetate present in a sample of human bodily fluid which comprised contacting said sample with a mixture comprising the following ingredients:
  - a) at least 20 U per ml. of  $\beta$ -HBD which has been obtained from a source such that it is inhibited by chloride ions,
  - b) NAD,
  - c) a nitroprusside salt or a diazonium salt in an amount sufficient to react with endogenous acetoacetate in the sample and acetoacetate obtained by conversion thereto of  $\beta$ -hydroxybutyrate in the sample, and
- d) a buffer having a pH of from about 8.6 to about 9.5, and measuring by electrochemical, spectrophotometric of flurometric means, or by comparison of the color developed to a preestablished color intensity standard, the amount of combined acetoacetate and  $\beta$ -hydroxybutyrate present in the sample.
- 61. A method according to Claim 60 wherein ingredient (c) is a nitroprusside salt.
- 62. A method according to Claim 61 wherein ingredient (c) is sodium nitroprusside.
- 63. A method according to Claim 60 wherein ingredient (c) is a diazonium salt.
- 64. A method according to Claim 63 wherein ingredients (c) is 4-nitrobenzene diazoium fluoborate.

- 65. A method according to Claim 60 having increased sensitivity wherein a tetrzolium dye precursor and an electron mediator are included in said mixture in addition to ingredients (a), (b), (c) and (d).
- 66. A method according to Claim 65 wherein the tetrazolium dye precursor is NBT or INT and the electron mediator is a diaphorase enzyme.
- 67. A method for monitoring the level of total ketone bodies present in a sample of human bodily fluid which comprises contacting said sample with a mixture containing
  - a) at least 20 U per ml. of  $\beta$ -HBD which has been obtained from a source such that it is inhibited by chloride ion,
  - b) NAD,
  - c) a nitroprusside or a diazonium salt in a quantity sufficient to
    - (i) react instantaneously with and stabilize against volatilization the acetone in the sample,
    - (ii) react with endogenous acetoacetate in the sample and
    - (iii) react with acetoacetate formed by conversion thereto of  $\beta$  hydroxybutyrate in the sample, and
  - d) a buffer having a pH of from about 8.6 to about 9.5, and measuring by electrochemncial, spectropotometric or fluormoetric means, or by comparison of the color developed to a preexisiting color intensity standard, the amount of total ketone bodies in the sample.

- 68. A method according to Claim 67 wherein ingredient (c) is a nitroprusside slat.
- 69. A method according to Claim 68 wherein ingredient (c) is a sodium nitroprusside.
- 70. A method according to Claim 67 wherein ingredient (c) is a diazonium slat.
- 71. A method according to Claim 70 wherein ingredient (c) is 4-nitrobenzene fluoborate.